A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
Public ClinicalTrials.gov record NCT03508700. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 40-week Open-Label Extension Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Evaluate the long-term safety of TNX-102 SL 5.6 mg taken daily at bedtime over an additional 40 weeks in patients with PTSD who have participated in a double-blind lead-in study and completed an initial 12-week open-label extension study (TNX-CY-P303).
Study identification
- NCT ID
- NCT03508700
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 93 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 19, 2018 (Actual)
- Primary completion
- Sep 30, 2019 (Actual)
- Completion
- Sep 30, 2019 (Actual)
- Last update posted
- Feb 5, 2025
2018 – 2019
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Little Rock | Little Rock | Arkansas | 72211 | — |
| Beverly Hills | Beverly Hills | California | 90210 | — |
| Oceanside | Oceanside | California | 92056 | — |
| Orange | Orange | California | 92868 | — |
| Temecula | Temecula | California | 92591 | — |
| Colorado Springs | Colorado Springs | Colorado | 80910 | — |
| Norwich | Norwich | Connecticut | 06360 | — |
| Tampa | Tampa | Florida | 33609 | — |
| Atlanta | Atlanta | Georgia | 30341 | — |
| New Bedford | New Bedford | Massachusetts | 02740 | — |
| Las Vegas | Las Vegas | Nevada | 89102 | — |
| Cedarhurst | Cedarhurst | New York | 11516 | — |
| New York | New York | New York | 10128 | — |
| Canton | Canton | Ohio | 44718 | — |
| Cincinnati | Cincinnati | Ohio | 45219 | — |
| Oklahoma City | Oklahoma City | Oklahoma | 73103 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03508700, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 5, 2025 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03508700 live on ClinicalTrials.gov.